Full-Time

Senior Director

Global Physician Partnerships

Posted on 9/26/2025

Deadline 10/3/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$173k - $299k/yr

+ Annual Performance Bonus + Long-term Incentive Program

Irvine, CA, USA

Remote

Field-based role available in all states within the United States.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Sales
Product Management
Marketing
Requirements
  • A Bachelor’s level degree is required, combined with 10 years of medical device work experience.
  • Minimum of 8 years of experience in a sales, marketing and/or product management role within interventional cardiology and structural heart is required.
  • Proven experience and success in working with healthcare professionals (HCPs) and KOLs, influencing without authority, and collaborating across functional teams.
  • Demonstrated track record partnership with clinical science, medical affairs, R&D, regulatory, sales and compliance is required.
  • Exceptional leadership, communication, and executive influence skills.
  • Strong financial competence and analytical skills with the ability to make data-driven decisions.
  • People management and experience developing talent required (3-5 years minimum).
  • Strategy planning, relationship building, customer focus, and strong communication skills is required.
  • Strong written and verbal communication skills, along with project management experience is required.
  • Ability to travel up to 50% is required.
Responsibilities
  • Define and implement the global strategic customer engagement vision and strategy for Cardiac Imaging & Structural Heart, aligning with business goals, regional needs and market evolution.
  • Provide leadership to the executive team on global market strategy, product roadmaps and service innovation through championing the voice of the global customer.
  • Work closely and collaboratively with counterparts and functions supporting the Electrophysiology business as well as other J&J cardiovascular business leaders and partners as needed.
  • Monitor international market dynamics, competitive positioning, and IC/Structural Heart trends to inform customer strategy and engagement initiatives.
  • Build and maintain a structured, repeatable infrastructure for IC engagement, including KOL mapping, society engagement plans, conference strategy, share of voice tracking, and systematic follow-up mechanisms for key interactions and related deliverables.
  • Integrate data-driven scientific and market insights into customer engagement strategies to drive targeted initiatives and measurable outcomes.
  • Mentor and influence a global network of strategic engagement professionals, ensuring alignment across regions and effective execution of customer strategies globally.
  • Develop and oversee systematic processes for internal follow-ups on physician interactions, ensuring insights are captured, responsibilities are assigned and actions are completed.
  • Establish and grow long-term relationships with key opinion leaders (KOLs), IC centers of excellence, academic institutions and large hospital systems globally.
  • Collaborate closely with clinical science, medical affairs, R&D, Regulatory, Marketing, Compliance, Sales and other internal functions to co-create plans, share in sights, align resources and ensure coordinated execution of physician/KOL engagement, conference strategy, voice of customer programs and product launches.
  • Engage with Interventional Cardiologists, opinion leaders, and societies to build advocacy and gain real-time market insights, managing relationships with key opinion leaders and external partners.
  • Establish and track key performance indicators and metrics to measure the effectiveness of physician engagement strategies.
  • Coordinate US Commercial advisory board meetings, providing insights to internal teams based on insights gathered from scientific conferences.
  • Support programs including new product launches, post-launch campaigns, post-market studies, symposia and commercially sponsored advisory boards.
  • Develop and implement a robust Voice of Customer (VOC) strategy and events applicable to physician opinion leaders, ensuring consistency and alignment of activities globally.
  • Establish internal alignment mechanisms (steering committees, cross domain review, shared dashboards) to ensure that insights from physician /KOL interactions cultivate into product development, clinical evidence generation and marketing messaging.
  • Collaborate with clinical affairs, medical affairs, regulatory, R&D, GSM, US Marketing, Commercial Education and New Technology Managers in support of organizational strategic plans and business objectives and to facilitate the external evaluation and launch of new technologies and marketing messaging.
  • Monitor and report on budget utilization, ensuring activities stay within financial targets while enhancing impact.
  • Conduct market analysis and stay informed about international IC therapy trends, KOLs, competitive positioning, and market dynamics to shape engagement strategies.
  • Conduct KOL mapping exercises to identify and understand leading national figures in IC.
  • Own the end-to-end conference and society engagement strategy and lead the cross-functional efforts to ensure success.
  • Develop strategies for leading critical issues related to physician relationships or product perceptions.
  • Represent the organization at international conferences, symposiums and industry forums as a key opinion leader.
Desired Qualifications
  • Master’s level degree is preferred.
  • Global experience preferred, with deep understanding of U.S. interventional cardiology and structural heart societies (TCT, CRT, SCAI, etc) and strong working relationship with IC.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE